MAP2K7 and melanoma: PRI-724 reduced the invasive capacity of melanoma cells resistant to trametinib, a MEK inhibitor, whereas it had no significant effect on the invasiveness of cells resistant to vemurafenib, a BRAFV600 inhibitor.